3 leading COVID-19 vaccines from India

World

Login / Sign Up

Saturday, September 26, 2020

Gold / Forex

3 leading COVID-19 vaccines from India

Regulators approve Phases II and III trials of COVID-19 shot in the subcontinent

Published: August 04, 2020 17:26 Jay Hilotin, Senior Assistant Editor

1 of 12

HOW SOON?: A COVID-19 shot could very well happen "soon", say experts. In India, several vaccine candidates are being developed by a number of homegrown biotech firms, including the Serum Institute of Inda (SII), Bharat Biotech International Ltd., Biological E, Indian Immunologicals and Zydus Cadila. The companies are either developing their own vaccine or have partnerships with other pharmaceutical giants. The Drugs Controller General of India is the authority responsible for approving a vaccine. Indian vaccine makers already produce hundreds of millions of doses against polio, meningitis, pneumonia, rotavirus, BCG, measles, mumps and rubella, among other diseases. Image Credit: REUTERS

2 of 12

WEB 200523 INDIA-SERUM33-1590225982007 — THREE VACCINES ON TRIAL IN INDIA. The subcontinent currently has three vaccines in different phases of human trials, Dr. Shriram Bhargava, director general of the Indian Council of Medical Research (ICMR), said on Tuesday. Photo shows a scientist working inside India's Serum Institute laboratory. Image Credit: REUTERS

3 of 12

SII vaccine trials — NOD FOR HUMAN TRIALS: On August 3, the Drugs Controller General of India (DCGI) has given approval to Pune-based Serum Institute of India (SII) to conduct clinical trials of Oxford University-Astra Zeneca COVID-19 vaccine in India. Image Credit: Twitter

4 of 12

VACCINE CHEAPER THAN WATER BOTTLE: On August 4, 2020, Dr Krishna Ella, Bharat Biotech's managing director, vowed to supply Covaxin to the whole world, at a cost — VACCINE PRICE 'AT LESS THAN WATER BOTTLE': On August 4, 2020, Dr Krishna Ella, Bharat Biotech's managing director, vowed to supply Covaxin to the whole world, at a cost "less than a water bottle." Dr. Ella worked as a research faculty at the Medical University of South Carolina, Charleston after earning his Ph.D. from the University of Wisconsin-Madison. Bharat Biotech, incorporated in 1996, has since become a global leader in vaccines. He also sits on the Scientific Advisory Committee in India's Union Cabinet. Image Credit: Bharat Biotech / YouTube screengrab

5 of 12

INACTIVATED VIRUS PLATFORM: The Clinical Trials Registry – India website states that Bharat Biotech will administer their COVID-19 shot, called Covaxin, on Day 0 and Day 14 of the trial. Bharat is using the inactivated virus vaccine platform, involving a heat-killed or dead virus that is used to generate an immune response. In the past, the company has also used this vaccine type to produce jabs for rabies, Japanese encephalitis and rotavirus. Image Credit: Gulf News

6 of 12

PHASE II CLINICAL TRIALS: On Tuesday (August 4, 2020), Dr Balram Bhargava, Director General of Indian Council of Medical Research (ICMR), claimed that vaccines from Bharat Biotech and Zydus Cadila Pharma have finished Phase-I Trials and will "soon" begin Phase II. India's Department of Biotechnology has funded Zydus Cadila's vaccine. The company had conducted pre-clinical studies on animals prior to Phase-I studies, which found an immune response in mice, rats, pigs and rabbits. Image Credit: Gulf News

7 of 12

Serum Institute will produce around 3-5 million doses per month, from now till September. The company says the Indian government will share some risk and fund the production with Serum. The company is set to spend between Rs300 million to Rs400 million to produce that volume. — Image Credit: Gulf News

8 of 12

MAJOR VACCINE PRODUCER: For many years, India has been rolling out other vaccines to different countries or via the UNICEF. The biggest challenges in vaccine development and production: prioritisation and fair distribution, logistics, stockpiling and training of people who are administering the shots. Image Credit: Gulf News / Jay Hilotin

9 of 12

Serum Institute of India (SII), the world’s largest maker of vaccines by volume, envisages a price of Rs1,000 ($13.20) per vaccine — but governments would give it to people without charge, said SII's Dr. Cyrus Poonawalla. — Image Credit: Gulf News

10 of 12

400 million doses planned Serum Institute of India plans to make the vaccine at its two manufacturing plants in the western city of Pune. The company aims to produce up to 400 million doses in 2021, if all goes well. — Image Credit: Gulf News

11 of 12

WEB 200523 INDIA-SERUM-1590225976638 — LAB WORK: India has reportedly prepared five sites for the final phase of human trials of the potential COVID-19 vaccine developed by Oxford. A research scientist works inside a laboratory of India's Serum Institute, the world's largest vaccine maker. Image Credit: REUTERS

12 of 12

Vaccine trial phases — HUMAN CLINICAL TRIAL PHASES: Phase I studies assess the safety of a drug or device. Phase II studies test the efficacy of a drug or device. Phase III studies involve a big number volunteers and is randomised, placebo-controlled and "blind" testing in several hundred to several thousand patients. Other candidate vaccines involve up to 30,000 volunteers. Image Credit: Gulf News /FDA

Latest In

Paris attack suspect wanted to target Charlie Hebdo

47 minutes ago
COVID-19: Stranded Filipino staff make desperate appeal

1 hour ago
COVID-19: Saudi patients can now travel for treatment

1 hour ago
Modi: India vaccine capacity will help ‘all humanity’

1 hour ago
COVID-19: Saudi Arabia reports 461 new infections

1 hour ago

This website stores cookies on your computer. These cookies are used to improve your experience and provide more personalized service to you. Both on your website and other media. To find out more about the cookies and data we use, please check out our Privacy Policy.

Trending